RxDoctor Payments Data

Scott Silver, DO

Internal Medicine · Las Vegas, NVNPI 1326333071

Payments from drug & device makers

$1,767in general payments, 2019–2025

Across 94 payments — averaging $18.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$738
  • Novartis$354
  • E.r. Squibb & Sons, L.L.C.$128
  • Veran Medical Technologies, Inc.$107
  • Intuitive Surgical$106
  • Novo Nordisk$100
  • plus $235 from 10 others

What the payments were for

  • Food & beverage$1,766100%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,767 in reported general payments places this provider in the 80th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$527,568
Medicare patients
849
Services billed
5,352

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban36$9,874
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen49$1,943
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen28$1,243
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$1,158
Divalproex Sodium18$790
Heparin SodiumHeparin Sodium,porcine26$759
Oxycodone Hcl37$584
Atorvastatin Calcium39$472
Isosorbide Mononitrate ErIsosorbide Mononitrate18$437
Hydralazine Hcl21$397
Omeprazole29$392
Losartan Potassium33$376
Carvedilol28$291
Ezetimibe18$286
Oxybutynin Chloride ErOxybutynin Chloride16$275

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$738$9,87436 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →